Cargando…
Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolit...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573832/ https://www.ncbi.nlm.nih.gov/pubmed/37834757 http://dx.doi.org/10.3390/jcm12196114 |
_version_ | 1785120552496660480 |
---|---|
author | Alameddine, Zakaria Abi Melhem, Racha Dimachkie, Reem Rabah, Hussein Chehab, Hamed El Khoury, Michel Qaqish, Faris Stefanov, Dimitre El-Sayegh, Suzanne |
author_facet | Alameddine, Zakaria Abi Melhem, Racha Dimachkie, Reem Rabah, Hussein Chehab, Hamed El Khoury, Michel Qaqish, Faris Stefanov, Dimitre El-Sayegh, Suzanne |
author_sort | Alameddine, Zakaria |
collection | PubMed |
description | Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A p-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, p = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment. |
format | Online Article Text |
id | pubmed-10573832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105738322023-10-14 Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment Alameddine, Zakaria Abi Melhem, Racha Dimachkie, Reem Rabah, Hussein Chehab, Hamed El Khoury, Michel Qaqish, Faris Stefanov, Dimitre El-Sayegh, Suzanne J Clin Med Brief Report Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A p-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, p = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment. MDPI 2023-09-22 /pmc/articles/PMC10573832/ /pubmed/37834757 http://dx.doi.org/10.3390/jcm12196114 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Alameddine, Zakaria Abi Melhem, Racha Dimachkie, Reem Rabah, Hussein Chehab, Hamed El Khoury, Michel Qaqish, Faris Stefanov, Dimitre El-Sayegh, Suzanne Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
title | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
title_full | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
title_fullStr | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
title_full_unstemmed | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
title_short | Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment |
title_sort | risk of nephrolithiasis in patients with inflammatory bowel disease receiving biologic treatment |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573832/ https://www.ncbi.nlm.nih.gov/pubmed/37834757 http://dx.doi.org/10.3390/jcm12196114 |
work_keys_str_mv | AT alameddinezakaria riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT abimelhemracha riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT dimachkiereem riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT rabahhussein riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT chehabhamed riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT elkhourymichel riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT qaqishfaris riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT stefanovdimitre riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment AT elsayeghsuzanne riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment |